REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

26 Sep 2023 01:29:00 By Nasdaq GlobeNewswire

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

25 Sep 2023 08:34:45 By Nasdaq GlobeNewswire

Regeneron Provides Update on Planned Chief Financial Officer Transition

08 Sep 2023 16:46:00 By Nasdaq GlobeNewswire

Regeneron Announces Updates to Board of Directors

08 Sep 2023 16:45:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

23 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention

22 Aug 2023 14:15:41 By Nasdaq GlobeNewswire

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

18 Aug 2023 18:35:00 By Nasdaq GlobeNewswire

Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease

18 Aug 2023 13:43:19 By Nasdaq GlobeNewswire

Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

17 Aug 2023 08:30:11 By Nasdaq GlobeNewswire

Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration

10 Aug 2023 07:00:00 By Nasdaq GlobeNewswire